Bank of New York Mellon Corp Purchases 15,412 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Bank of New York Mellon Corp lifted its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 9.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 174,742 shares of the medical instruments supplier’s stock after purchasing an additional 15,412 shares during the quarter. Bank of New York Mellon Corp owned about 0.44% of AngioDynamics worth $1,057,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new stake in shares of AngioDynamics during the 4th quarter valued at $6,272,000. Fund 1 Investments LLC bought a new stake in AngioDynamics during the fourth quarter worth about $3,896,000. Western Standard LLC increased its stake in shares of AngioDynamics by 878.5% during the first quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock valued at $3,072,000 after purchasing an additional 469,906 shares in the last quarter. Kennedy Capital Management LLC lifted its holdings in shares of AngioDynamics by 425.0% during the first quarter. Kennedy Capital Management LLC now owns 190,236 shares of the medical instruments supplier’s stock valued at $1,117,000 after purchasing an additional 154,002 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of AngioDynamics in the 4th quarter worth approximately $1,042,000. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Price Performance

ANGO stock opened at $7.54 on Friday. The stock has a market capitalization of $302.01 million, a P/E ratio of -1.56 and a beta of 0.65. AngioDynamics, Inc. has a 1-year low of $5.26 and a 1-year high of $8.25. The business has a fifty day moving average price of $7.45 and a 200-day moving average price of $6.50.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.11. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The business had revenue of $71.00 million during the quarter, compared to analyst estimates of $70.86 million. During the same quarter in the previous year, the firm earned $0.02 EPS. AngioDynamics’s revenue was down 22.1% on a year-over-year basis. As a group, analysts anticipate that AngioDynamics, Inc. will post -0.41 earnings per share for the current year.

Analysts Set New Price Targets

ANGO has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a research note on Friday. Canaccord Genuity Group lowered their price target on AngioDynamics from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Wednesday, July 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, AngioDynamics has an average rating of “Moderate Buy” and an average target price of $12.25.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.